To test HER2-positive and HER2-negative cells’ response to vit-D3 treatment, exponentially growing breast cancer cells were exposed to increasing concentrations of vit-D3 for 24 h, 48 h, and 72 h, and the viability of cells was determined by SRB assay. This evidence concerns the gene ERBB2 and breast carcinoma.